Clinical trials: Papillomavirus Infection
Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18
A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.
A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16…
- Conditions
- Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Cervical Intraepithelial Neoplasia
- Trial name
- NCT02733068
- Testing
- HPV-16/18 vaccine
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Anogenital Warts, Condylomata Acuminata
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
The purpose of this study is to determine the safety, tolerability and efficacy of the topical application of AP611074 5% gel during 6 weeks on ano-genital warts caused by human papillomavirus (HPV).
- Conditions
- Anogenital Warts, Condylomata Acuminata, Human Papillomavirus Infection
- Trial name
- NCT01532102
- Testing
- AP611074
- Where
- 4 sites in Argentina, France
- Volunteers
- 24 people
- Sponsor
- Anaconda Pharma
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00122681
- Testing
- Cervarix™, Havrix™-based investigational formulation
- Where
- 138 sites in United States, Australia and 12 more
- Volunteers
- 18,729 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
The purpose of this study is to establish the long-term persistence of the immune response and safety of the HPV vaccine in healthy females who were aged 9 to 25 years in the primary study (NCT00541970).
- Trial name
- NCT02100618
- Testing
- Blood sampling
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV Infections, Cervical Cancer
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT04895020
- Testing
- 9-valent HPV vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Vulvar Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
The purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00520598
- Testing
- Comparator: V505 formulation 1, Comparator: V505 formulation 2, Comparator: V505 formulation 3
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Warts, Human Papilloma Virus
Candin Safety & Efficacy Study for the Treatment of Warts
The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
- Trial name
- NCT01757392
- Testing
- Candida albicans Skin Test Antigen
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Nielsen BioSciences, Inc.
Infection by Human Papilloma Virus
Dynamics of Human PApilloma Virus Interactions; Internet-based Students HeAlth Research Enterprise
Human papillomavirus (HPV) infection is the most common sexually transmitted infection. The high risk oncogenic types, HPV-16 and -18 are responsible for 70% of cervical cancers.
- Trial name
- DyPAVIR (NCT01988948)
- Testing
- Various biological sampling
- Where
- France
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
HPV Infection, Lesion Cervix
Investigation to Evaluate PAPILOCARE® Gel Effect on Normalization of Cervix Cytological Alterations Caused by HPV.
Observational clinical study, national, multicentric, prospective, non-comparative, with medical device, under application consistent with CE marking, for the evaluation of Papilocare® effectivness in the normalization of cervix…
- Trial name
- PAPILOBS (NCT04199260)
- Testing
- papilocare vaginal gel
- Where
- 9 sites in Spain
- Volunteers
- 263 people
- Sponsor
- Procare Health Iberia S.L.
Cervical Intraepithelial Neoplasia
A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection
This randomized, double-blind, placebo-controlled, parallel arm study will assess the safety and the efficacy of RO5217790 on histologic resolution in participants with high grade CIN associated with HR-HPV infection.
- Trial name
- NCT01022346
- Testing
- RO5217790
- Where
- 66 sites in United States, Belgium and 4 more
- Volunteers
- 206 people
- Sponsor
- Hoffmann-La Roche
HPV Infection
Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections
to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for the treatment of patients with cervical high-risk HPV infections; to analyze the HPV type infections and clinical negative conversion.
- Trial name
- NCT01824992
- Testing
- Yallaferon®
- Volunteers
- 325 people
- Sponsor
- Lee's Pharmaceutical Limited
Warts
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks.
- Trial name
- NCT00115141
- Testing
- Resiquimod
- Volunteers
- 88 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Human Papillomavirus (HPV) Infection, HPV (Human Papillomavirus)-Associated Carcinoma
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
This vaccine was jointly developed by Chengdu Institute of Biological Products Co., Ltd. and National Vaccine and Serum Institute, China, is co-sponsoring this clinical trial.
- Trial name
- NCT06632912
- Testing
- 2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha), 3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
- Where
- 3 sites in China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Human Papillomavirus Infection
An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain
The purpose of this study is to determine the Human Papillomavirus (HPV) prevalence and HPV type distribution among women ≥ 20 years of age attending routine cervical screening and among women ≥ 16 years of age presenting for…
- Trial name
- NCT01205412
- Testing
- Endocervical samples
- Where
- Bahrain
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus, Cervical Cancer
Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia
This study aims to determine the prevalence of human papillomavirus (HPV) and to assess the HPV type distribution among women >= 15 years of age, attending routine gynaecological examination in the Kingdom of Saudi Arabia.
- Trial name
- NCT01213459
- Testing
- Cervical samples, Data collection
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Common Wart
OM202JP Clinical Study of KNP2002
The goal of this clinical trial is to evaluate safety and efficacy of KNP2002 in patients with common warts aged 15 to 50 years old.
- Trial name
- NCT05896215
- Testing
- KNP2002
- Where
- 15 sites in Japan
- Volunteers
- 159 people
- Sponsor
- KinoPharma Inc.
HPV Infections
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult women
- Trial name
- NCT00378560
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Warts
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW.
- Trial name
- NCT00735462
- Testing
- 2.5% imiquimod cream, 3.75% imiquimod cream
- Where
- 43 sites in United States
- Volunteers
- 511 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Infections, Papillomavirus
Cervarix Long-term Safety Surveillance
This study aims to assess whether the use of Cervarix® is associated with a modified risk of central demyelination, type 1 diabetes (DT1), Cutaneous Lupus, inflammatory arthritis, idiopathic thrombocytopenic purpura (ITP), Lupus…
- Trial name
- PGRx (NCT01498627)
- Testing
- Cervarix, Data collection
- Volunteers
- 2,945 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Papillomavirus Infections
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
The present study is a multicenter, open, non-interventional, prospective observational clinical study for the evaluation of the effectiveness of Papilocare® (medical device with CE mark) in the regression of cervix cytological…
- Trial name
- PAPILOBSGR (NCT06399341)
- Testing
- Papilocare vaginal gel
- Where
- 4 sites in Greece
- Volunteers
- 524 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.